Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Placebo gel is a pharmacologically inactive topical formulation developed by Bayer for use as a control in clinical trials, specifically those evaluating BAY H006689 (a 10% naproxen topical gel). It is designed to be physically indistinguishable from the active study drug in terms of appearance, odor, and texture, but it contains no active pharmaceutical ingredient. In the context of muscle and joint pain studies, it is used to establish a baseline for safety, tolerability, and skin irritation (such as in cumulative irritant patch tests) to differentiate the effects of the vehicle from the effects of the active naproxen component.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo gel.